Certified Global Research Member

Key Questions Answered

Global Market Outlook
In-depth analysis of global and regional trends
Analyze and identify the major players in the market, their market share, key developments, etc.
To understand the capability of the major players based on products offered, financials, and strategies.
Identify disrupting products, companies, and trends.
To identify opportunities in the market.
Analyze the key challenges in the market.
Analyze the regional penetration of players, products, and services in the market.
Comparison of major playersâ€™ financial performance.
Evaluate strategies adopted by major players.
Recommendations

Why Choose Market Research Future?

Vigorous research methodologies for specific market.
Knowledge partners across the globe
Large network of partner consultants.
Ever-increasing/ Escalating data base with quarterly monitoring of various markets
Trusted by fortune 500 companies/startups/ universities/organizations
Large database of 5000+ markets reports.
Effective and prompt pre- and post-sales support.

Granulocyte Macrophage Colony Stimulating Factor Companies

Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) is a naturally occurring protein in the body that stimulates the production and function of white blood cells, including granulocytes and macrophages. GM-CSF is used therapeutically in medicine to boost the immune system, particularly in individuals undergoing certain medical treatments. Companies involved in GM-CSF development and manufacturing play a crucial role in providing therapeutic solutions.

Granulocyte-Macrophage Colony-Stimulating Factor Key Companies

Latest Granulocyte-Macrophage Colony-Stimulating Factor Companies Update

Chugai Pharmaceutical The leading manufacturer of filgrastim (Granulocyte) announced plans to expand their global production capacity due to increasing demand for the GM-CSF therapy.

Coherus BioSciences Received US FDA approval for Udencya, a biosimilar version of pegfilgrastim, offering a more affordable alternative for managing chemotherapy-induced neutropenia.

Kyowa Hakko Kirin Developed a long-acting GM-CSF variant (NKTR-102) in collaboration with Nektar Therapeutics, demonstrating promising efficacy in clinical trials for neutropenia prevention.

List of Granulocyte-Macrophage Colony-Stimulating Factor Key Companies in the Market

Xconomy Inc.

Partner Therapeutics (PTx)

Sanofi-Aventis U.S. LLC

Novartis AG

Thermo Fisher Scientific

Merck KGaA

Granulocyte Macrophage Colony Stimulating Factor Companies

Leading companies partner with us for data-driven Insights

Kindly complete the form below to receive a free sample of this Report

Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
	Single User	$ 4,950
	Multiuser License	$ 5,950
	Enterprise User	$ 7,250
Compare Licenses

Tailored for You

Dedicated Research on any specifics segment or region.
Focused Research on specific players in the market.
Custom Report based only on your requirements.
Flexibility to add or subtract any chapter in the study.
Historic data from 2014 and forecasts outlook till 2040.
Flexibility of providing data/insights in formats (PDF, PPT, Excel).
Provide cross segmentation in applicable scenario/markets.